RT Journal Article
SR Electronic
T1 Monitoring the propagation of SARS CoV2 variants by tracking identified mutation in wastewater using specific RT-qPCR
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.10.21253291
DO 10.1101/2021.03.10.21253291
A1 S Wurtzer
A1 P Waldman
A1 M Levert
A1 JM Mouchel
A1 O Gorgé
A1 M Boni
A1 Y Maday
A1 OBEPINE consortium
A1 V Marechal
A1 L Moulin
YR 2021
UL http://medrxiv.org/content/early/2021/03/20/2021.03.10.21253291.abstract
AB Since the end of 2020, the COVID-19 pandemic has experienced a major turning point with the appearance and rapid spread of new variants, causing a significant increase in the number of new cases requiring hospitalization. These so-called UK, South African or Brazilian variants are characterized by combinations of mutations which allow them to be distinguished from the variants which have circulated since the start of the epidemic. The impact of these variants on the functioning of healthcare systems requires monitoring the spread of these variants, which are more contagious, more lethal and may reinfect people who are already immune to a natural infection or to a vaccination. Monitoring the viral genome in wastewater has shown great value in early detection of the dynamics of virus spreading in populations.The sequencing of viral genomes is used in humans, but its application and interpretation on wastewater matrices are much more complex due to the diversity of circulating strains. Also this study demonstrates the possibility of following certain mutations found in these new variants by targeted RT-qPCR. This study is the first carried out in France demonstrating the spreading dynamics of the 69-70 deletion in the Spike protein of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was cofounded by the French ministery of research and innovation, Eau de Paris and Sorbonne university.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We did not use clinical human samples in our studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data are available